Zacks: Analysts Anticipate Jasper Therapeutics, Inc. (NASDAQ:JSPR) to Announce -$0.37 Earnings Per Share

Equities research analysts expect Jasper Therapeutics, Inc. (NASDAQ:JSPRGet Rating) to announce earnings of ($0.37) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Jasper Therapeutics’ earnings. The company is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Jasper Therapeutics will report full year earnings of ($1.30) per share for the current year, with EPS estimates ranging from ($1.40) to ($1.18). For the next year, analysts anticipate that the business will post earnings of ($1.45) per share, with EPS estimates ranging from ($1.50) to ($1.39). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Jasper Therapeutics.

Several research firms have recently issued reports on JSPR. Credit Suisse Group dropped their price objective on shares of Jasper Therapeutics from $15.00 to $10.00 and set an “outperform” rating on the stock in a report on Friday, February 25th. Zacks Investment Research upgraded shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, January 20th. Finally, Cantor Fitzgerald assumed coverage on shares of Jasper Therapeutics in a research report on Monday, February 28th. They set an “overweight” rating and a $10.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $15.00.

A number of large investors have recently added to or reduced their stakes in JSPR. Abingworth LLP acquired a new position in shares of Jasper Therapeutics during the third quarter worth approximately $58,030,000. Morgan Stanley acquired a new position in shares of Jasper Therapeutics during the third quarter worth approximately $1,117,000. Tudor Investment Corp Et Al acquired a new position in shares of Jasper Therapeutics during the third quarter worth approximately $205,000. Citadel Advisors LLC acquired a new position in shares of Jasper Therapeutics during the third quarter worth approximately $29,215,000. Finally, Jane Street Group LLC acquired a new position in shares of Jasper Therapeutics during the third quarter worth approximately $267,000. Hedge funds and other institutional investors own 63.03% of the company’s stock.

Shares of NASDAQ:JSPR remained flat at $$2.97 on Tuesday. 31,464 shares of the stock traded hands, compared to its average volume of 81,154. The firm’s 50 day moving average price is $3.18 and its 200 day moving average price is $5.48. Jasper Therapeutics has a one year low of $2.45 and a one year high of $18.88.

About Jasper Therapeutics (Get Rating)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.

Further Reading

Get a free copy of the Zacks research report on Jasper Therapeutics (JSPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jasper Therapeutics (NASDAQ:JSPR)

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.